Literature DB >> 33502077

Lentiginous melanoma (lentigo maligna and lentigo maligna melanoma) in Australia: clinicopathological characteristics, management and recurrence rates after 10-year follow-up at a tertiary centre.

H Collgros1,2, E Rodriguez-Lomba3, A Regio Pereira1,2,4, S N Lo5, R A Scolyer5,6,7, P Guitera1,2,5.   

Abstract

BACKGROUND: Lentiginous melanoma or lentigo maligna is a slow-growing type of melanoma frequently arising in sun-damaged skin and often first diagnosed in the elderly. Few studies report long-term follow-up.
OBJECTIVES: To define characteristics of lentiginous melanoma in situ (LM) and invasive lentiginous melanoma (LMM) in Australian patients managed at a tertiary centre and describe local recurrence or treatment failure rates after long-term follow-up.
METHODS: Retrospective single-centre study of LM/LMM patients evaluated between January 2005 and March 2007. Medical and photographic records were reviewed.
RESULTS: One hundred two patients were included, with a total of 117 lesions (70 LM and 47 LMM). Seventy-nine were new primary LM/LMM, and 38 were recurrences. Primary cases were mostly pigmented (71%), while 77% of recurrent cases were partially pigmented/light brown or amelanotic. The margins were clinically ill-defined in the majority of cases (64% of primary cases and 94% of recurrent cases). Dermoscopy of the primary LM/LMM showed either classic 'common' melanoma features (33%) or classic LM/LMM features (41%), while 95% of recurrent cases had no features for melanoma or LM/LMM. Primary cases that were initially excised (113, 97%) had mean histopathological clear margins of 4.9 mm (range 0.1-22 mm). The median follow-up time was 7.5 years (95% CI 5.2-10.0) with more than 10-year follow-up in 32% and 5-10 years in 24% of patients. There were 44 (38%) recurrences over the entire follow-up period. Half of the patients who recurred did so within the first 3.8 years after the first treatment.
CONCLUSION: LM/LMM often recur late and are clinically subtle; therefore, careful monitoring and long-term follow-up are required.
© 2021 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2021        PMID: 33502077     DOI: 10.1111/jdv.17135

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  1 in total

1.  Re: Reply to letter to the editor re: 'practical guide on the use of imiquimod cream to treat lentigo maligna'.

Authors:  Pascale Guitera; Andreanne Waddell; Elizabeth Paton; Gerald B Fogarty; Angela Hong; Richard A Scolyer; Jonathan R Stretch; Brett A O'Donnell; Giovanni Pellacani
Journal:  Australas J Dermatol       Date:  2022-02-02       Impact factor: 2.481

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.